Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
July 25, 2024 07:00 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
Nasdaq Reports Second Quarter 2024 Results; Strong Performance Across All Divisions with Double-Digit Solutions Growth
July 25, 2024 07:00 ET
|
Nasdaq, Inc.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq: NDAQ) today reported financial results for the second quarter of 2024. Second quarter 2024 net revenues1 were $1.2 billion, an...
Garrett Motion Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Outlook
July 25, 2024 06:58 ET
|
Garrett Motion Inc.
Garrett Motion Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Outlook
Visteon Announces Second Quarter 2024 Results
July 25, 2024 06:55 ET
|
Visteon Corporation
VAN BUREN TOWNSHIP, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Visteon Corporation (NASDAQ: VC) today reported second quarter financial results. Highlights include: Sales of $1,014 million with...
Huize Announces Strategic Partnership with New China Life Insurance to Jointly Launch “Bliss” – A Customized Annuity Insurance Product
July 25, 2024 06:45 ET
|
Huize Holding Limited
SHENZHEN, China, July 25, 2024 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance...
AirSculpt Technologies Announces Second Quarter Fiscal 2024 Earnings Release Date and Conference Call
July 25, 2024 06:45 ET
|
Airsculpt Technologies, Inc.
MIAMI BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium body contouring procedures, today announced it will...
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
July 25, 2024 06:30 ET
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
Donegal Group Inc. Announces Second Quarter and First Half 2024 Results
July 25, 2024 06:30 ET
|
Donegal Group, Inc.
MARIETTA, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Donegal Group Inc. (NASDAQ: DGICA) and (NASDAQ: DGICB) today reported its financial results for the second quarter and first half of 2024. ...
Amalgamated Financial Corp. Reports Second Quarter 2024 Financial Results; Continued Stellar Deposit Growth; Return on Average Assets of 1.30%
July 25, 2024 06:25 ET
|
Amalgamated Financial Corp.
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Amalgamated Financial Corp. (the “Company” or “Amalgamated”) (Nasdaq: AMAL), the holding company for Amalgamated Bank (the “Bank”), today announced...
FirstCash Reports Second Quarter Operating Results; U.S. Pawn Fees Grow 22%, Driving 25% Increase in U.S. Pawn Segment Earnings; 47 Pawn Locations Added in Second Quarter Through Acquisitions and New Store Openings; Quarterly Cash Dividend Increased to $0.38 per Share
July 25, 2024 06:00 ET
|
FirstCash, Inc.
FORT WORTH, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- FirstCash Holdings, Inc. (“FirstCash” or the “Company”) (Nasdaq: FCFS), the leading international operator of more than 3,000 retail pawn stores...